Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-09-18
1999-08-03
Martinell, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 245, 435 6, 435375, A61K 4800, C12N 1511
Patent
active
059325569
ABSTRACT:
Methods and compositions are provided for the treatment of immune system-mediated diseases. The compositions of the invention have the property of reducing the expression of CD28 in cells of interest so as to moderate the pathogenic effects on the immune system in an immune system-mediated disease. The compositions of the invention include one or more different oligomers capable of reducing the expression of CD28. One aspect of the invention provides oligomers capable of reducing the expression of CD28 by interfering with its expression. The oligomers may be DNA, RNA, or various analogs thereof, and may include 14-50 base phosphorothioates having at least two sequences of GGGG separated by 3 to 5 bases. Other aspects of the invention provide genetic engineering vectors for the intracellular expression of oligomers of the invention in cells of interest, and formulations comprising one or more different oligomers of the invention. The formulations may be adapted for various forms of administration to the body or administration to cells to be reintroduced into the body. The methods of the invention involve modulating CD28 expression through the use of the oligomers of the invention. The methods may be used to treat immune system-mediated diseases and include methods of treating autoimmune disease, methods of reducing an inflammation response, methods of reducing the production of selected cytokines, methods of inactivating T cells, and methods of immunosuppressing a transplant patient.
REFERENCES:
Rojanasakul Y. "Antisense oligonucleotide therapeutics: drug delivery and targeting," Adv. Drug Deliery Rev., vol. 18: 115-131, 1996.
Miller et al. "Gene Transfer and Antisense Nucleic Acid Techniques," Parasitology Today, vol. 10: 92-97, Mar. 1994.
Wu Pong S. "Oligonucleotides: Opportunities for Drug Therapy and Research," Pharaceutical Technology, vol. 18: 102-114, Oct. 1994.
Stull et al. "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," Pharmaceutical Research, vol. 12: 465-483, Apr. 1995.
Wagner et al. "Gene inhibition using antisense oligodeoxynucleotides," Nature, vol. 372: 333-335, Nov. 1994.
Stein et al. "Antisense Oligonucleotides as Therapeutic Agents-Is the Bullet Really Majical?," Science, vol. 261: 1004-1012, Aug. 1993.
Weiss et al. "Upping the Antisense Ante," Science News, vol. 139: 108-109, 1991.
Gross et al. "The murine homologue of the T lymphocyte antigen CD28," J. of Immunology, vol. 144, No. 8, pp. 3201-3210, 1990.
Aruffo et al. "Molecular cloning of a CD28 cDNA by a high-efficiency COS expression system," vol. 84, No. 23: 8573-8577, 1987.
Uhlmann et al. "Antisense Oligonucleotides: A New Therpeutic Principle," Chemical Reviews, vol. 90, No. 4: 543-584, 1990.
Schultz et al. "Refined solution structure of the dimeric quadruplex formed from the Oxytricha telomeric oligonucleotide d(GGGGTTTTGGGG)," vol. 2, No. 3: 10718-10724, Mar. 1994.
Eck et al. "Gene-Based Therapy," Gooman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York, Chapter 5, 1995.
Bennett, C. F., Chiang, M. Y., Wilson-Lingardo, L., Wyatt, J. R. (1994) Nucleic Acids Res. 22, 3202-3209.
Burgess, T. L., Fisher, E. F., Ross, S. L., Bready, J. V., Qian, Y.-X., Bayewitch, L. A., Cohen, A. M., Herrera, C. J., Hu, S. S.-F., Kramer, T. B., Lott, F. D., Martin, F. H., Pierce, G. F., Simonet, L., Farrell, C. L. (1995) Proc. Natl. Acad. Sci. USA 92, 4051-4055).
Fish Robert D.
Hauda Karen M.
Martinell James
LandOfFree
Methods and compositions for regulation of CD28 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for regulation of CD28 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for regulation of CD28 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-849571